BioSpace News Archive

Biosense Webster, Inc. announced that positive results from the company-sponsored STELLAR study were presented as a late breaker, titled “Pulmonary Vein Isolation of Paroxysmal Atrial Fibrillation with Multielectrode Radiofrequency Balloon Catheter: Results from the Global, Multicenter, STELLAR Study,” at the 28th Annual International AF Symposium.

Takeda announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the expanded use of TAKHZYRO® for prophylaxis to prevent attacks of hereditary angioedema in pediatric patients 2 to <12 years of age.

Senti Biosciences, Inc. announced that effective on February 1, 2023, the Compensation Committee of Senti Bio’s Board of Directors granted to 13 new employees stock options to purchase an aggregate of 309,000 shares of the Company’s common stock with a per share exercise price of $1.81.

Prothena Corporation plc announced that in connection with hiring a new employee, the compensation committee of the Company’s board of directors granted the individual hired by the Company an option to purchase 85,000 ordinary shares of the Company.

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its ARM vaccine manufacturing

Sorrento Therapeutics, Inc. distributed dividend confirmation statements to 146 brokerage firms regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento.

Orexo AB, announces the submission of a New Drug Application to the US Food and Drug Administration for its lead pharmaceutical pipeline asset, OX124, a nasal rescue medication for opioid overdose.

Dexlevo, a company specializing in aesthetic medical devices, successfully held a symposium dedicated to its exclusive product, ‘GOURI’, at the IMCAS World Congress 2023 in Paris.

Midatech Pharma PLC announces that it received written notification from The NASDAQ Stock Market LLC, dated 31 January 2023, stating that the Company is not in compliance with the minimum bid price requirement set forth in NASDAQ’s rules for continued listing on The NASDAQ Capital Market.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2022 and provided a business update.